The data from 2023 shows France leading with the highest tax revenue in pollution-related taxes in the manufacturing of chemicals and basic pharmaceuticals at $51.71 million (2015 PPP dollars), experiencing a 7.75% increase. The Netherlands, Poland, and the United Kingdom follow, though they saw declines of 2.21%, 1.71%, and 9.02%, respectively. Sweden maintained stability, while Denmark and Slovakia experienced drops. Smaller markets like Slovenia and Finland witnessed significant decreases, reflecting broader challenges or policy shifts. Notably, Belgium faced a notable decline of over 23%, whereas Serbia and Switzerland achieved modest growth.
Future trends to watch:
- Monitoring the impact of evolving environmental regulations on tax revenues across Europe.
- Potential technological advancements enhancing efficiency, possibly reducing pollution and, subsequently, tax revenues.
- The interplay between industrial growth and environmental sustainability targets, influencing tax impacts.
Top countries in Environmentally Related Tax Revenue from Taxes on Pollution in Manufacturing of Chemicals, Basic Pharmaceuticals and Preparations Share by Country (Million US Dollars PPP = 2015)
| # | 10 Countries | Percent | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 France | 51.71 | 2023 | +6.84% | +7.75% | View data |
| 2 | 2 Netherlands | 15.07 | 2023 | +3.7% | -2.21% | View data |
| 3 | 3 Poland | 8.55 | 2023 | -2.94% | -1.71% | View data |
| 4 | 4 United Kingdom | 6.94 | 2023 | -10.76% | -9.02% | View data |
| 5 | 5 Sweden | 5.39 | 2023 | -0.94% | +0.0069% | View data |
| 6 | 6 Denmark | 4.21 | 2023 | -0.59% | -1.83% | View data |
| 7 | 7 Slovakia | 3.37 | 2023 | -6.45% | -7.89% | View data |
| 8 | 8 Czech Republic | 1.53 | 2023 | -8.79% | -6.95% | View data |
| 9 | 9 Lithuania | 0.9 | 2023 | -0.2% | -4.22% | View data |
| 10 | 10 Serbia | 0.82 | 2023 | +0.61% | +2.15% | View data |
Latest reports
US Pharmaceuticals Market Report- Q4 2024
In the fourth quarter of 2024, the US pharmaceuticals market exhibited robust growth across various segments, driven by strategic investments, regulatory advancements, and...
Japan Pharmaceuticals Market Report- Q4 2024
The Japanese pharmaceutical industry in Q4 2024 exhibits dynamic shifts driven by government policies, market demand, and strategic innovations. The continuous rise of...
Germany Pharmaceuticals Market Report- Q4 2024
The fourth quarter of 2024 presented a multifaceted landscape for the German pharmaceuticals industry, characterized by economic pressures, regulatory changes, and evolving consumer...
India Pharmaceuticals Market Report- Q4 2024
The Indian pharmaceutical industry in Q4 2024 continues to show dynamic growth, fueled by advancements in biologics and biosimilars, substantial export activities, and...
UK Pharmaceuticals Market Report- Q4 2024
The UK Pharmaceuticals market in Q4 2024 faced a dynamic landscape shaped by economic, regulatory, and competitive factors. Amidst inflationary pressures and evolving...
France Pharmaceuticals Market Report- Q4 2024
The French pharmaceuticals market in the fourth quarter of 2024 was marked by significant developments across various segments, including biopharmaceuticals, generic drugs, over-the-counter...
Canada Pharmaceuticals Market Report- Q4 2024
In the fourth quarter of 2024, the Canadian pharmaceuticals market showcased dynamic growth and adaptation across various segments. The evolving landscape was influenced...
Brazil Pharmaceuticals Market Report- Q4 2024
The Brazil pharmaceuticals market in Q4 2024 is characterized by significant trends and strategic developments across various segments. The demand for generic pharmaceuticals...
Italy Pharmaceuticals Market Report- Q4 2024
The fourth quarter of 2024 presents a dynamic landscape for the pharmaceuticals market in Italy, characterized by significant trends and strategic developments across...
South Korea Pharmaceuticals Market Report- Q1 2025
The first quarter of 2025 has been pivotal for the pharmaceuticals industry in South Korea, marked by significant growth in the biopharmaceuticals and...
